Protein degrading breast cancer drugs navigate bumpy road to market
By 
Andy Extance2026-09-15T14:00:00
Camizestrant is now approved in US, UK and Europe despite uncertainty over long-term benefit, while vepdegestrant is approved in the US
The US Food and Drug Administration (FDA) has granted limited approval to two innovative protein-degrading drugs for breast cancer, even though evidence for their overall effectiveness is unclear. In early September, the FDA granted accelerated approval to AstraZeneca’s Etcamah (camizestrant),